anti-Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) Antibodies

The precise function of PARK2 is unknown\; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Additionally we are shipping PARK2 Kits (21) and PARK2 Proteins (12) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
PARK2 5071 O60260
PARK2 56816 Q9JK66
PARK2 50873 Q9WVS6
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-PARK2 Antibodies at antibodies-online.com

Showing 10 out of 194 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-Park2 Antibody Titration: 0.2-1 ug/mlELISA Titer: 1:312500Positive Control: Mouse Liver 100 μL Log in to see 2 to 3 Days
$319.00
Details
Human Mouse Un-conjugated ELISA, IF, WB Immunofluorescence of monoclonal antibody to PARK2 on HeLa cell (antibody concentration 10 µg/mL). PARK2 monoclonal antibody (M01), clone 1H4 Western Blot analysis of PARK2 expression in Jurkat. 100 μg Log in to see 8 to 11 Days
$527.50
Details
Cow Rabbit Un-conjugated IC, IF, WB Immunofluorescent analysis of Parkin staining in HepG2 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue). Western blot analysis of Parkin expression in HepG2 (A), SHSY5Y (B), SW480 (C) whole cell lysates. 200 μL Log in to see 13 to 14 Days
$487.50
Details
Human Rabbit Un-conjugated ICC, IHC (p), WB Anti- Parkin Picoband antibody, IHC(P) IHC(P): Human Intestinal Cancer Tissue Anti- Parkin Picoband antibody, IHC(P) IHC(P): Mouse Brain Tissue 100 μg Log in to see 4 to 6 Days
$280.00
Details
Human Rabbit Un-conjugated IHC, ELISA, WB Western blot analysis of extracts from Jurkat cells, using Parkin Antibody. The lane on the right is treated with the synthesized peptide. Immunohistochemistry analysis of paraffin-embedded human brain tissue, using Parkin Antibody. The picture on the right is treated with the synthesized peptide. 100 μg Log in to see 2 to 3 Days
$302.50
Details
Human Rabbit Un-conjugated IHC, ELISA Immunohistochemistry analysis of paraffin-embedded human skeletal muscle, using Parkin (Phospho-Ser131) Antibody. The picture on the right is treated with the synthesized peptide. 100 μg Log in to see 2 to 3 Days
$302.50
Details
Human Rabbit Un-conjugated IHC, ELISA, WB Western blot analysis of extracts from HeLa/HuvEc cells, using Parkin (Ab-131) Antibody. The lane on the right is treated with the synthesized peptide. Immunohistochemistry analysis of paraffin-embedded human brain tissue, using Parkin (Ab-131) Antibody. The picture on the right is treated with the synthesized peptide. 100 μg Log in to see 2 to 3 Days
$302.50
Details
Human Rabbit Un-conjugated FACS, IF, IHC (p), WB Western blot analysis of anti-PARK2 (Parkin) Antibody (N-term) (ABIN390365) in NCI-H460 cell line lysates (35 µg/lane). PARK2 (Parkin)(arrow) was detected using the purified polyclonal antibody. Western blot analysis of lysates from SH-SY5Y cell line, human brain tissue lysate (from left to right), using Park2 Antibody (N-term)(ABIN2840771). ABIN2840771 was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysates at 20ug per lane. 400 μL Log in to see 10 to 11 Days
$385.00
Details
Human Rabbit Un-conjugated FACS, IF, IHC (p), WB The anti-Parkin C-term Pab (ABIN390366) is used in Western blot to detect Parkin in mouse kidney tissue lysate. Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. BC = breast carcinoma. HC = hepatocarcinoma 400 μL Log in to see 10 to 11 Days
$385.00
Details
Human Rabbit Un-conjugated ELISA, IHC Western Blot (WB) analysis of 293T AD293 HeLa using p-Parkin (S131) antibody. 100 μL Log in to see 16 Days
$181.73
Details

Top referenced anti-PARK2 Antibodies

  1. Human Polyclonal PARK2 Primary Antibody for ELISA, WB - ABIN545403 : Yao, Gu, Nakamura, Shi, Ma, Gaston, Palmer, Rockenstein, Zhang, Masliah, Uehara, Lipton: Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. in Proceedings of the National Academy of Sciences of the United States of America 2004 (PubMed)
    Show all 3 Pubmed References

  2. Human Polyclonal PARK2 Primary Antibody for IHC (p), ELISA - ABIN545404 : Pigullo, De Luca, Barone, Marchese, Bellone, Colosimo, Scaglione, Martinelli, Di Maria, Pizzuti, Abbruzzese, Dallapiccola, Ajmar, Mandich: Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. in Parkinsonism & related disorders 2004 (PubMed)
    Show all 3 Pubmed References

  3. Human Polyclonal PARK2 Primary Antibody for IHC (p), IP - ABIN269703 : La Cognata, Iemmolo, DAgata, Scuderi, Drago, Zappia, Cavallaro: Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene. in Current genomics 2014 (PubMed)
    Show all 2 Pubmed References

  4. Human Polyclonal PARK2 Primary Antibody for ELISA, WB - ABIN251684 : Scuderi, La Cognata, Drago, Cavallaro, DAgata: Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. in BioMed research international 2014 (PubMed)
    Show all 2 Pubmed References

  5. Human Monoclonal PARK2 Primary Antibody for IF, WB - ABIN2476069 : Ostby: [Fredrik Nightingale fellows]. in Journalen sykepleien 1990 (PubMed)
    Show all 2 Pubmed References

  6. Cow (Bovine) Polyclonal PARK2 Primary Antibody for WB - ABIN550123 : Jenner, Dexter, Sian, Schapira, Marsden: Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. in Annals of neurology 1992 (PubMed)
    Show all 2 Pubmed References

  7. Human Polyclonal PARK2 Primary Antibody for WB - ABIN550126 : Yamamoto, Friedlein, Imai, Takahashi, Kahle, Haass: Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. in The Journal of biological chemistry 2005 (PubMed)
    Show all 2 Pubmed References

  8. Human Polyclonal PARK2 Primary Antibody for IF (p), IHC (p) - ABIN735578 : Li, Zhang, Wang, Liu, Yang, Liu, Lu: Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant ?-synuclein. in Phytomedicine : international journal of phytotherapy and phytopharmacology 2014 (PubMed)

  9. Human Monoclonal PARK2 Primary Antibody for IF, ELISA - ABIN562106 : Brody, Taylor, Wilson, Delatycki, Lockhart: Regional and cellular localisation of Parkin co-regulated gene in developing and adult mouse brain. in Brain research 2008 (PubMed)

More Antibodies against PARK2 Interaction Partners

Fruit Fly (Drosophila melanogaster) Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) interaction partners

  1. Parkin null mutation is associated with climbing defects and defects and mitochondrial activity.

  2. Loss of parkin is associated with nuclear clustering and morphology defects in larval muscles and thus developing aortic aneurysms.

  3. This study found learning and memory abnormalities in Parkin mutant genotypes in Drosophila.

  4. parkin mutants have a longer lifespan when fed the 1:16 P:C compared to those fed the 1:2 P:C diet. Parkin mutants fed the 1:16 P:C diet have delayed climbing deficit, increased resistance to starvation. Mutant flies fed the 1:16 P:C diet also have improved mitochondrial functions as evidenced by increased respiratory control ratio

  5. Drosophila CHIP protects against mitochondrial dysfunction by acting downstream of Pink1 in parallel with Parkin

  6. Maintenance of tissue homeostasis upon reduction of Pink1 or Parkin appears to result from reduction of age- and stress-induced intestinal stem cell proliferation, in part, through induction of ISC senescence.

  7. activation of endoplasmic reticulum stress by defective mitochondria is neurotoxic in pink1 and parkin flies and that the reduction of this signalling is neuroprotective, independently of defective mitochondria.

  8. Pharmacological or genetic activation of heat shock protein 70 (Hsp70) protects against loss of parkin Function. Heat shock protein members may act as compensatory factors for parkin loss of function and that the exploitation of these factors may be of potential therapeutic value.

  9. autophosphorylation of PINK1 is essential for the mitochondrial translocation of Parkin and for subsequent phosphorylation and activation of Parkin.

  10. Our data indicate that PINK1 and Parkin play an important role in FUS-induced neurodegeneration. This study has uncovered a previously unknown link between FUS proteinopathy and PINK1/Parkin genes, providing new insights into the pathogenesis of FUS proteinopathy.

  11. Clu is upstream of and binds to VCP in vivo and promotes VCP-dependent Marf degradation in vitro Marf accumulates in whole muscle lysates of clu-deficient flies and is destabilized upon Clu overexpression. Thus, Clu is essential for mitochondrial homeostasis and functions in concert with Parkin and VCP for Marf degradation to promote damaged mitochondrial clearance.

  12. Buffy has a role enhancing the loss of parkin and suppressing the loss of Pink1 phenotypes in Drosophila

  13. Parkin-dependent mitophagy suppresses neural neurodegeneration by removing damaged mitochondria.

  14. We demonstrate here that vps35 genetically interacts with parkin

  15. Clu directly modulates mitochondrial function, and that Clu's function contributes to the PINK1-Park pathway of mitochondrial quality control.

  16. Human Mask homolog ANKHD1 may serve as a potential therapeutic target for treating Parkinson disease caused by pink1/parkin mutations.

  17. These results indicate that the in vivo rescue is due to restoring CI activity rather than promoting mitophagy Our findings support the emerging view that PINK1 plays a role in regulating CI activity separate from its role with Parkin in mitophagy

  18. MUL1 acts in parallel to the PINK1/parkin pathway on a shared target mitofusin to maintain mitochondrial integrity.

  19. Parkin cooperates with PINK1 to promote hnRNP-F/Glo ubiquitination and nRCC mRNA translation.

  20. The loss-of-function mutation in parkin results in defective immune response against bacterial infection. Additionally, parkin mutant larvae showed hypersensitivity against wound regardless of bacterial infection.

Human Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) interaction partners

  1. work provides a framework for the mechanisms of parkin's loss-of-function, indicating an interplay between ARJP-associated substitutions and phosphorylation of its Ubl domain.

  2. Data show that E3 ubiquitin-protein ligase parkin (Parkin) undergoes a conformational change upon phosphorylation.

  3. carnosic acid induces parkin by enhancing the ubiquitination of ARTS, leading to induction of XIAP.

  4. PARK2 promoter SNP's rs2276201 and rs9347683 are shown to be significantly associated with the risk of colorectal cancer development

  5. Increased levels of Parkin are detected in lens epithelial cells exposed to H2O2-oxidative stress. Parkin translocates to mitochondria of lens epithelial cells upon H2O2-oxidative stress exposure. Parkin ubiquitin ligase activity is required for clearance of damaged mitochondria in lens epithelial cells exposed to H2O2-oxidative stress.

  6. Examined the enzymatic activity of Parkin with M458L mutation. We show that the M458L mutant retains its autoubiquitination potential in vitro but not in cells. M458L mutant fails to protect the mitochondria against hydrogen peroxide, leading to cell death.

  7. The results demonstrate that Nix can serve as an alternative mediator of mitophagy to maintain mitochondrial turnover, identifying Nix as a promising target for neuroprotective treatment in PINK1/Parkin-related Parkinson's disease.

  8. Female patients with PARK2 polymorphism had significantly higher risk of VTE recurrence

  9. Studies indicate a functional PTEN-induced putative kinase 1)(PINK1)/E3 ubiquitin protein ligase (parkin) mitophagy pathway in neurons [Review].

  10. indings indicate that PRKN mutations are associated with large global gene expression changes as observed in fibroblasts from PRKN-Parkinson's disease patients

  11. parkin deficiency induces synaptotagmin-11 accumulation and PD-like neurotoxicity in mouse models, which is reversed by SYT11 knockdown in the SNpc or knockout of SYT11 restricted to dopaminergic neuron

  12. Parkin expression is inversely correlated with HIF-1alpha expression and metastasis in breast cancer. Results reveal an important mechanism for Parkin in tumor suppression and HIF-1alpha regulation.

  13. mitochondrial dysfunction activates the PINK1/Parkin signaling and mitophagy in renal tubular epithelial cells under albumin overload condition.

  14. The authors demonstrate that RABGEF1, the upstream factor of the endosomal Rab GTPase cascade, is recruited to damaged mitochondria via ubiquitin binding downstream of Parkin. RABGEF1 directs the downstream Rab proteins, RAB5 and RAB7A, to damaged mitochondria, whose associations are further regulated by mitochondrial Rab-GAPs.

  15. DNAJ proteins keep Parkin C289G mutant protein in a soluble, degradation-competent form.

  16. S-nitrosylated PINK1 decreases Parkin translocation to mitochondrial membranes

  17. Parkinsonism associated with Parkin gene mutation is one of the most common familial forms of Parkinson Disease, which is characterized by early onset of symptoms, slow progression, elective dopaminergic neuronal loss and the absence of Lewy bodies.

  18. A transcriptional repressor network including THAP domain containing 11 protein (THAP11) was identified and negatively regulates endogenous PARKIN abundance.

  19. Study explored the role of parkin proteins in Parkinson's disease (PD) neurodegeneration by analyzing their expression profile in an in vitro model exposed to divers neurotoxins. Results showed that up- or down-regulation of specific splice isoforms may be a direct effect of toxin exposure. Moreover, the isoforms may exert different actions in neurodegeneration via modulation of different molecular pathways.

  20. Mutations in the PARK2 gene were detected in four of the six tested families with a history of early-onset Parkinson disease.

Zebrafish Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) interaction partners

  1. Melatonin, added together with MPTP or added once MPTP was removed, prevented and recovered, respectively, the parkinsonian phenotype once it was established, restoring gene expression and normal function of the parkin/PINK1/DJ-1/MUL1 loop and also the normal motor activity of the embryos.

Pig (Porcine) Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) interaction partners

  1. Single nucleotide polymorphism (SNP) analysis revealed seven SNPs in the porcine PARK2 gene, one missense and one silent mutation in exon 7 and five SNPs in intron 7

Mouse (Murine) Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) interaction partners

  1. Parkin functions to blunt excessive CHOP to prevent maladaptive ER stress-induced cell death and adverse cardiac ventricular remodeling.

  2. data suggested that suppressed Sirt3-Foxo3A-Parkin signaling mediated downregulation of mitophagy may play a vital role in the development of diabetic cardiomyopathy.

  3. Overexpression of parkin resulted in a significant reduction of total-eNOS and p-eNOS in parallel with the downregulation of ERRalpha (a regulator of eNOS) protein and the enhancement of ERRalpha ubiquitination.

  4. Parkin mice carrying a deletion in exon 3 display impairments in the main pathway responsible for maintaining BH4 levels in the CNS, an essential cofactor for dopamine synthesis, under inflammatory conditions. Concomitant to this alteration, striatum cells do not upregulate BDNF to confer neuroprotection in LPS-exposed mice, displaying an increased number of mitochondria of smaller size with perinuclear clustering.

  5. the results indicate that PICK1 is a potent inhibitor of Parkin, and the reduction of PICK1 enhances the protective effect of Parkin.

  6. PINK1 and PARK2 suppress pancreatic tumorigenesis through control of mitochondrial iron-mediated immunometabolism

  7. When fed with iron-supplemented diet, DMT1-expressing mice exhibit rather selective accumulation of iron in the substantia nigra but otherwise seem normal. Parkin expression is also enhanced, likely as a neuroprotective response. When DMT1 is overexpressed against a Parkin null background, the double-mutant mice similarly resisted a disease phenotype when fed with iron or manganese, but greater susceptibility to 6-OHDA.

  8. Bnip3l knockout (bnip3l(-/-)) impaired mitophagy and aggravated cerebral I-R (ischemia-reperfusion) injury in mice, which can be rescued by BNIP3L overexpression. The rescuing effects of BNIP3L overexpression can be observed in park2(-/-) mice, which showed mitophagy deficiency after I-R.

  9. Parkin acts as a regulator of microtubule system during neuronal aging.

  10. The expression of PINK1 and Parkin were elevated in white adipose tissue in obese mice.

  11. crossed Parkin knockouts to the Twinkle-TG mouse in which mtDNA deletions are increased specifically in substantia nigra to determine the effect of increased deletion mutagenesis in the absence of mitochondrial quality control

  12. These findings reveal parkin-mediated cytoprotective mechanisms against misfolded SOD1 toxicity.

  13. Park2 deficiency exacerbates ethanol-induced dopaminergic neuron damage through p38 kinase dependent inhibition of autophagy and mitochondrial function.

  14. PARK2-dependent acidic postconditioning -induced mitophagy renders the brain resistant to ischemic injury.

  15. Our results indicate that strict maternal transmission of mitochondria relies on mitophagy and uncover a collaboration between MUL1 and PARKIN in this process.

  16. an impaired PINK1-PARK2-mediated neuroimmunology pathway contributes to septic death.

  17. These findings suggest that insufficient mitophagy-mediated PDGFR/PI3K/AKT activation, which is mainly attributed to reduced PARK2 expression, is a potent underlying mechanism for myofibroblast differentiation and proliferation in fibroblastic foci formation during idiopathic pulmonary fibrosis pathogenesis

  18. Mfn2 downregulation or the exogenous expression of normal Parkin restored cytosolic Ca(2+) transients in fibroblasts from patients with PARK2 mutations, a catalytically inactive Parkinson's disease (PD)-related Parkin variant had no effect. Parkin is directly involved in regulating ER-mitochondria contacts and provide new insight into the role of the loss of Parkin function in PD development

  19. Our results provide a molecular explanation for the contribution of Drp1 to the pathogenesis of sporadic Parkinson's disease (PD). These findings indicate that the SNO-Parkin pathway may be a novel therapeutic target to treat PD

  20. These results suggest a previously unidentified role of parkin in mediating endotoxin-induced endothelial proinflammatory signaling and indicate that it may play a critical role in acute inflammation.

PARK2 Antigen Profile

Protein Summary

The precise function of this gene is unknown\; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support.

Gene names and symbols associated with PARK2

  • parkin (park) antibody
  • parkin RBR E3 ubiquitin protein ligase (PRKN) antibody
  • parkin RBR E3 ubiquitin protein ligase (Prkn) antibody
  • parkin RBR E3 ubiquitin protein ligase (prkn) antibody
  • parkin (CpipJ_CPIJ014867) antibody
  • Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) antibody
  • AR-JP antibody
  • CG10523 antibody
  • Dmel\\CG10523 antibody
  • Dpark antibody
  • dpk antibody
  • LPRS2 antibody
  • Park antibody
  • PARK2 antibody
  • PDJ antibody
  • pdr-1 antibody
  • Prkn antibody
  • SD01679 antibody
  • si:ch211-123f21.1 antibody
  • zgc:112390 antibody

Protein level used designations for PARK2

CG10523-PB , CG10523-PC , D-parkin , dparkin , park-PB , park-PC , E3 ubiquitin-protein ligase parkin , Parkinson disease (autosomal recessive, juvenile) 2, parkin , parkinson juvenile disease protein 2 , parkin variant SV5DEL , parkin , parkin protein , parkinson protein 2, E3 ubiquitin protein ligase (parkin)

GENE ID SPECIES
40336 Drosophila melanogaster
5071 Homo sapiens
56816 Rattus norvegicus
550328 Danio rerio
733673 Sus scrofa
741350 Pan troglodytes
6049109 Culex quinquefasciatus
50873 Mus musculus
612316 Canis lupus familiaris
100724550 Cavia porcellus
530858 Bos taurus
Selected quality suppliers for anti-PARK2 (PARK2) Antibodies
Did you look for something else?